SCHEMBL4589478

SCHEMBL4589478

CCNC(=O)N1CCCN(c2ccc(C(=O)OC)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
MAPT P10636 7/20 0.48
KMT2A Q03164 3/20 0.48
MLLT1 Q03111 1/20 0.47
CXCR3 P49682 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
TSHR P16473 2/20 0.46
HPGD P15428 1/20 0.45
POLB P06746 1/20 0.45
GFER P55789 2/20 0.45
NPC1 O15118 2/20 0.45
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
MAPK1 P28482 2/20 0.44
RAB9A P51151 2/20 0.44
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20907444 0.83 TP53 (0.61) ALDH1A1MAPTKMT2ASMN1; SMN2TSHR
SCHEMBL64400 0.83 ALDH1A1 (0.57) ALDH1A1MAPTKMT2ASMN1; SMN2TSHR
SCHEMBL20897465 0.82 ALDH1A1 (0.71) ALDH1A1MAPTKMT2ASMN1; SMN2TSHR
SCHEMBL5322691 0.82 KDM4E (0.67) ALDH1A1MAPTCXCR3SMN1; SMN2HPGD
SCHEMBL13979594 0.80 CXCR3 (0.49) KMT2ACXCR3SMN1; SMN2NPC1RAB9A
SCHEMBL2951325 0.79 ALDH1A1 (0.71) ALDH1A1MAPTKMT2ASMN1; SMN2TSHR
SCHEMBL4589173 0.78 ALDH1A1 (0.57) ALDH1A1MAPTKMT2ASMN1; SMN2HPGD
SCHEMBL5742108 0.78 ALDH1A1 (0.69) ALDH1A1MAPTKMT2ASMN1; SMN2TSHR
SCHEMBL4116463 0.78 MAPT (0.69) ALDH1A1MAPTKMT2ASMN1; SMN2TSHR
SCHEMBL64850 0.78 SMN1; SMN2 (0.57) ALDH1A1MAPTKMT2ASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312215-A1 Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312215-A1 Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders CXCR3, CXCR1, CX3CR1 ALDH1A1 1053/4885MAPT 4702/4885KMT2A 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.